




Docket No.: 205907US0PCT

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231



ATTORNEYS AT LAW

RE: Application Serial No.: 09/830,669
Applicants: Philippe MARLIERE, et al.
Filing Date: April 30, 2001
For: PROCESS FOR PRODUCING CHEMICALLY
DIVERSIFIED PROTEINS, IN VIVO, BY
INCORPORATING UNCONVENTIONAL AMINO
ACIDS
Group Art Unit: 1636
Examiner: LEFFERS

SIR:

Attached hereto for filing are the following papers:

Response to Restriction Requirement (3 pp.)

Our check in the amount of \$0.00 is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Norman F. Oblon
Attorney of Record
Registration No. 24,618



22850

(703) 413-3000 (phone)
(703) 413-2220 (fax)

Vincent K. Shier, Ph.D.
Registration No. 50,552

RECEIVED
SEP 24 2002
JECH CENTER 1600/2900

DOCKET NO.: 205907US0PCT



IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF:

Philippe MARLIERE, et al.

SERIAL NO.: 09/830,669

FILED: APRIL 30, 2001

:

: GROUP ART UNIT: 1636

:

: EXAMINER: LEFFERS

FOR: METHOD FOR PRODUCING IN VIVO PROTEINS CHEMICALLY
DIVERSIFIED BY INCORPORATING NON-STANDARD AMINO ACIDS

TECH CENTER 1600/2900

SEP 24 2002

RECEIVED

#9

RESPONSE TO RESTRICTION REQUIREMENT

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

Responsive to the Official Action dated August 21, 2002, Applicants elect, with
traverse, Group I, Claims 1-14 and 18 for further prosecution.

REMARKS

The Office has required restriction in the present application as follows:

- Group I: Claims 1-14 and 18, drawn to processes for selection of cells capable of expressing a protein essential for the cell's growth and a selected cell;
- Group II: Claims 15-17 and 19-34, drawn to methods of selecting cells comprising an aminoacyl-tRNA synthetase capable of charging at tRNA capable of recognizing a missense mutation with an unconventional amino acid, selected cells and methods of using such cells to produce a polypeptide comprising an unconventional amino acid;
- Group III: Claims 35-46, drawn to methods of purifying the protein comprising the unconventional amino acid and the purified protein;
- Group IV: Claims 47-49, diagnostic packs and methods of using the purified protein as part of a diagnostic composition; and